Table of Contents
ISRN Inflammation
Volume 2012, Article ID 898153, 8 pages
http://dx.doi.org/10.5402/2012/898153
Research Article

Anti-Inflammatory Effects of Urocanic Acid Derivatives in Models Ex Vivo and In Vivo of Inflammatory Bowel Disease

1Department of Dermatology, Academic Medical Center (AMC), University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
2Tytgat Institute for Liver and Intestinal Research, Academic Medical Center (AMC), University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
3Pathology Department, Academic Medical Center (AMC), University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands

Received 20 June 2012; Accepted 30 July 2012

Academic Editors: L. J. Hofseth and F. Klebl

Copyright © 2012 Arthur Kammeyer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Abraham and J. H. Cho, “Inflammatory bowel disease,” The New England Journal of Medicine, vol. 361, no. 21, pp. 2066–2078, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Subramanian, J. M. Rhodes, C. A. Hart et al., “Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine,” Inflammatory Bowel Diseases, vol. 14, no. 2, pp. 162–175, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Andoh, Y. Yagi, M. Shioya, A. Nishida, T. Tsujikawa, and Y. Fujiyama, “Mucosal cytokine network in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 14, no. 33, pp. 5154–5161, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. S. R. Targan, S. B. Hanauer, S. J. H. Van Deventer et al., “A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's Disease,” The New England Journal of Medicine, vol. 337, no. 15, pp. 1029–1035, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. S. B. Hanauer, W. J. Sandborn, P. Rutgeerts et al., “Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial,” Gastroenterology, vol. 130, no. 2, pp. 323–332, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Bouguen, J. B. Chevaux, and L. Peyrin-Biroulet, “Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases,” World Journal of Gastroenterology, vol. 17, no. 5, pp. 547–556, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Nerich, E. Monnet, A. Etienne et al., “Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data,” Inflammatory Bowel Diseases, vol. 12, no. 3, pp. 218–226, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Nerich, P. Jantchou, M. C. Boutron-Ruault et al., “Low exposure to sunlight is a risk factor for Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 8, pp. 940–945, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Sonnenberg, D. J. McCarty, and S. J. Jacobsen, “Geographic variation of inflammatory bowel disease within the United States,” Gastroenterology, vol. 100, no. 1, pp. 143–149, 1991. View at Google Scholar · View at Scopus
  10. L. Peyrin-Biroulet, A. Oussalah, and M. A. Bigard, “Crohn's disease: the hot hypothesis,” Medical Hypotheses, vol. 73, no. 1, pp. 94–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. R. S. Sandler, “The incidence of IBD is higher in the North,” Inflammatory Bowel Diseases, vol. 4, no. 2, pp. 175–176, 1998. View at Google Scholar · View at Scopus
  12. D. L. Damian, Y. J. Matthews, T. A. Phan, and G. M. Halliday, “An action spectrum for ultraviolet radiation-induced immunosuppression in humans,” British Journal of Dermatology, vol. 164, no. 3, pp. 657–659, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Kammeyer, T. A. Eggelte, H. Overmars, A. Bootsma, J. D. Bos, and M. B. M. Teunissen, “Oxidative breakdown and conversion of urocanic acid isomers by hydroxyl radical generating systems,” Biochimica et Biophysica Acta, vol. 1526, no. 3, pp. 277–285, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. N. K. Gibbs, J. Tye, and M. Norval, “Recent advances in urocanic acid photochemistry, photobiology and photoimmunology,” Photochemical and Photobiological Sciences, vol. 7, no. 6, pp. 655–667, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Kammeyer, J. Garssen, A. Sleijffers et al., “Suppression of different phases of systemic contact hypersensitivity by urocanic acid oxidation products,” Photochemistry and Photobiology, vol. 80, no. 1, pp. 72–77, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Kammeyer, J. D. Bos, and M. B. M. Teunissen, “Postelicitation model of allergic contact dermatitis for predicting the efficacy of topical drugs,” Experimental Dermatology, vol. 18, no. 1, pp. 44–49, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Albert, J. Walker, A. Thiesen, T. Churchill, and K. Madsen, “cis-urocanic acid attenuates acute dextran sodium sulphate-induced intestinal inflammation,” PLoS ONE, vol. 5, no. 10, Article ID e13676, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Jürgens, R. P. Laubender, F. Hartl et al., “Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis,” American Journal of Gastroenterology, vol. 105, no. 8, pp. 1811–1819, 2010. View at Publisher · View at Google Scholar · View at Scopus